Raffaele Ratta1, Annalisa Guida2, Florian Scotté3, Yann Neuzillet4, Asmahane Benmaziane Teillet3, Thierry Lebret4, Philippe Beuzeboc3. 1. Oncology and Supportive Care Department, Hôpital Foch, Suresnes, France. r.ratta@hopital-foch.com. 2. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. 3. Oncology and Supportive Care Department, Hôpital Foch, Suresnes, France. 4. Urology Department, Hôpital Foch, Suresnes, France.
Abstract
BACKGROUND: A great number of DNA-damage repair (DDR) pathways have been recognized to be frequently dysregulated in advanced stages of prostate cancer. DNA-repair defects in prostate cancer represents a clinically relevant disease subset. Tumors whose ability to repair double-strand DNA breaks by homologous recombination is compromised, are highly sensitive to blockade of the repair of DNA single-strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase (PARP). METHODS: A systematic review of the literature has been conducted in January 2020 using PubMed Medline database in line with the recommendations from the PRISMA guidelines. The following string terms were used for searching clinical trial articles: castration resistant OR castrate resistance OR castration refractory AND prostate cancer AND PARP OR poly(ADP-ribose) polymerase inhibitor OR DNA-repair OR homologous recombination repair. On-going clinical trials with olaparib, niraparib, talazoparib, veliparib, and rucaparib in mCRPC were searched on the clinicalTrials.gov website. RESULTS: From this research 176 articles were identified. After title screening and abstract reading, five papers and four abstract were considered for the systematic review. Thirty-two clinical trials were also identified: from these 16 trials which did not include mCRPC patients or only prostate cancer patients, trials not yet recruiting and trials including radio-metabolic treatments were excluded. Sixteen trials were included and discussed in the paper. CONCLUSIONS: Olaparib has been the first agent showing a benefit in terms of rPFS and ORR alone or in combination with abiraterone plus prednisone in patients with DDR deficiency prostate cancer. Also rucaparib showed a benefit in terms of PSA response rate and ORR in patients with BRCA2 and BRCA1 mutation in a phase-II study. Other phase-III clinical trials are evaluating niraparib and talazoparib, alone or in combination with AR signaling inhibitors.
BACKGROUND: A great number of DNA-damage repair (DDR) pathways have been recognized to be frequently dysregulated in advanced stages of prostate cancer. DNA-repair defects in prostate cancer represents a clinically relevant disease subset. Tumors whose ability to repair double-strand DNA breaks by homologous recombination is compromised, are highly sensitive to blockade of the repair of DNA single-strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase (PARP). METHODS: A systematic review of the literature has been conducted in January 2020 using PubMed Medline database in line with the recommendations from the PRISMA guidelines. The following string terms were used for searching clinical trial articles: castration resistant OR castrate resistance OR castration refractory AND prostate cancer AND PARP OR poly(ADP-ribose) polymerase inhibitor OR DNA-repair OR homologous recombination repair. On-going clinical trials with olaparib, niraparib, talazoparib, veliparib, and rucaparib in mCRPC were searched on the clinicalTrials.gov website. RESULTS: From this research 176 articles were identified. After title screening and abstract reading, five papers and four abstract were considered for the systematic review. Thirty-two clinical trials were also identified: from these 16 trials which did not include mCRPC patients or only prostate cancerpatients, trials not yet recruiting and trials including radio-metabolic treatments were excluded. Sixteen trials were included and discussed in the paper. CONCLUSIONS:Olaparib has been the first agent showing a benefit in terms of rPFS and ORR alone or in combination with abiraterone plus prednisone in patients with DDR deficiency prostate cancer. Also rucaparib showed a benefit in terms of PSA response rate and ORR in patients with BRCA2 and BRCA1 mutation in a phase-II study. Other phase-III clinical trials are evaluating niraparib and talazoparib, alone or in combination with AR signaling inhibitors.
Authors: Daniel J Farrugia; Mukesh K Agarwal; Vernon S Pankratz; Amie M Deffenbaugh; Dmitry Pruss; Cynthia Frye; Linda Wadum; Kiley Johnson; Jennifer Mentlick; Sean V Tavtigian; David E Goldgar; Fergus J Couch Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Sean T Martin; Hiroyuki Matsubayashi; Carmelle D Rogers; Juliet Philips; Fergus J Couch; Kieran Brune; Charles J Yeo; Scott E Kern; Ralph H Hruban; Michael Goggins Journal: Oncogene Date: 2005-05-19 Impact factor: 9.867
Authors: Elena Castro; Chee Goh; Daniel Leongamornlert; Ed Saunders; Malgorzata Tymrakiewicz; Tokhir Dadaev; Koveela Govindasami; Michelle Guy; Steve Ellis; Debra Frost; Elizabeth Bancroft; Trevor Cole; Marc Tischkowitz; M John Kennedy; Jacqueline Eason; Carole Brewer; D Gareth Evans; Rosemarie Davidson; Diana Eccles; Mary E Porteous; Fiona Douglas; Julian Adlard; Alan Donaldson; Antonis C Antoniou; Zsofia Kote-Jarai; Douglas F Easton; David Olmos; Rosalind Eeles Journal: Eur Urol Date: 2014-11-06 Impact factor: 20.096
Authors: Catherine S Grasso; Yi-Mi Wu; Dan R Robinson; Xuhong Cao; Saravana M Dhanasekaran; Amjad P Khan; Michael J Quist; Xiaojun Jing; Robert J Lonigro; J Chad Brenner; Irfan A Asangani; Bushra Ateeq; Sang Y Chun; Javed Siddiqui; Lee Sam; Matt Anstett; Rohit Mehra; John R Prensner; Nallasivam Palanisamy; Gregory A Ryslik; Fabio Vandin; Benjamin J Raphael; Lakshmi P Kunju; Daniel R Rhodes; Kenneth J Pienta; Arul M Chinnaiyan; Scott A Tomlins Journal: Nature Date: 2012-07-12 Impact factor: 49.962
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245
Authors: Elena Castro; Chee Goh; David Olmos; Ed Saunders; Daniel Leongamornlert; Malgorzata Tymrakiewicz; Nadiya Mahmud; Tokhir Dadaev; Koveela Govindasami; Michelle Guy; Emma Sawyer; Rosemary Wilkinson; Audrey Ardern-Jones; Steve Ellis; Debra Frost; Susan Peock; D Gareth Evans; Marc Tischkowitz; Trevor Cole; Rosemarie Davidson; Diana Eccles; Carole Brewer; Fiona Douglas; Mary E Porteous; Alan Donaldson; Huw Dorkins; Louise Izatt; Jackie Cook; Shirley Hodgson; M John Kennedy; Lucy E Side; Jacqueline Eason; Alex Murray; Antonis C Antoniou; Douglas F Easton; Zsofia Kote-Jarai; Rosalind Eeles Journal: J Clin Oncol Date: 2013-04-08 Impact factor: 44.544
Authors: Joshua Armenia; Stephanie A M Wankowicz; David Liu; Jianjiong Gao; Ritika Kundra; Ed Reznik; Walid K Chatila; Debyani Chakravarty; G Celine Han; Ilsa Coleman; Bruce Montgomery; Colin Pritchard; Colm Morrissey; Christopher E Barbieri; Himisha Beltran; Andrea Sboner; Zafeiris Zafeiriou; Susana Miranda; Craig M Bielski; Alexander V Penson; Charlotte Tolonen; Franklin W Huang; Dan Robinson; Yi Mi Wu; Robert Lonigro; Levi A Garraway; Francesca Demichelis; Philip W Kantoff; Mary-Ellen Taplin; Wassim Abida; Barry S Taylor; Howard I Scher; Peter S Nelson; Johann S de Bono; Mark A Rubin; Charles L Sawyers; Arul M Chinnaiyan; Nikolaus Schultz; Eliezer M Van Allen Journal: Nat Genet Date: 2018-04-02 Impact factor: 38.330
Authors: Maren T Scheuner; Kenute Myrie; Jane Peredo; Lori Hoffman-Hogg; Margaret Lundquist; Stephanie L Guerra; Douglas Ball Journal: Fed Pract Date: 2020-08
Authors: Matthew R Smith; Howard I Scher; Shahneen Sandhu; Eleni Efstathiou; Primo N Lara; Evan Y Yu; Daniel J George; Kim N Chi; Fred Saad; Olof Ståhl; David Olmos; Daniel C Danila; Gary E Mason; Byron M Espina; Xin Zhao; Karen A Urtishak; Peter Francis; Angela Lopez-Gitlitz; Karim Fizazi Journal: Lancet Oncol Date: 2022-02-04 Impact factor: 54.433